P345: AN IMMUNE SCREEN IDENTIFIES 5-NONLOXYTRYPTAMINE AS A NOVEL ANTI-CANCER AGENT CAPABLE OF IMPROVING ANTI-TUMOR IMMUNITY IN COMBINATION WITH ANTI-PD1 THERAPY

P345: AN IMMUNE SCREEN IDENTIFIES 5-NONLOXYTRYPTAMINE AS A NOVEL ANTI-CANCER AGENT CAPABLE OF IMPROVING ANTI-TUMOR IMMUNITY IN COMBINATION WITH ANTI-PD1 THERAPY

Bibliographic Details
Main Authors:	P. Stachura, W. Liu, A. Wlodarczyk, C. Xu, S. Bhatia, P. A. Lang, A. Borkhardt, A. A. Pandyra
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000844268.82216.4a

Similar Items

Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors
by: Paweł Stachura, et al.
Published: (2023-08-01)

Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents
by: Monica A. Kamal, et al.
Published: (2023-09-01)

Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy
by: Elaine Lai-Han Leung, et al.
Published: (2023-08-01)

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model
by: Rūta Veinalde, et al.
Published: (2023-01-01)

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
by: Yi Huang, et al.
Published: (2024-12-01)

Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer
by: Marine Baron, et al.
Published: (2022-03-01)

Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
by: Soyeon Lim, et al.
Published: (2023-01-01)

NEW ASPECTS OF ANTI-INFECTION IMMUNITY
by: E. P. Kisseleva
Published: (2014-06-01)

S-allylmercaptocysteine promotes anti-tumor immunity by suppressing PD-L1 expression
by: Jianxiong Zhao, et al.
Published: (2023-05-01)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
by: Zihan Zhao, et al.
Published: (2023-03-01)

Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
by: Shuming Chen, et al.
Published: (2024-03-01)

Characteristics of Anti-Measles Immunity in Lung Transplant Candidates
by: Valentina B. Polishchuk, et al.
Published: (2023-10-01)

Senescent Tumor CD8<sup>+</sup> T Cells: Mechanisms of Induction and Challenges to Immunotherapy
by: Wei Liu, et al.
Published: (2020-09-01)

1154 Anti-PD-L1 antibody-immune modulator conjugates significantly enhance anti-tumor activity in syngeneic models
by: Chul-Woong Chung, et al.
Published: (2023-11-01)

Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy
by: Maria Luigia Carbone, et al.
Published: (2023-08-01)

AntiPD-L1 antibody conjugated Au-SPIOs nanoplatform for enhancing radiosensitivity and triggering anti-tumor immune response
by: Chengrun Du, et al.
Published: (2022-11-01)

Role of Methylation in Pro- and Anti-Cancer Immunity
by: Ali Mehdi, et al.
Published: (2021-02-01)

Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity
by: Louis F. Chai, et al.
Published: (2021-07-01)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
by: Enikő Sebestyén, et al.
Published: (2023-10-01)

Enhancement of the Anti-Inflammatory Activity of NSAIDs by Their Conjugation with 3,4,5-Trimethoxybenzyl Alcohol
by: Paraskevi Tziona, et al.
Published: (2022-03-01)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
by: Patrick Williams, et al.
Published: (2023-10-01)

Anagrelide is an anti-megakaryocytic and not an anti-platelet agent
by: Steve P. Watson, et al.
Published: (2019-01-01)

The Role of Leptin in Childhood Immune Thrombocytopenia (ITP): An Anti-Inflammatory Agent?
by: Iason Thomas, et al.
Published: (2021-07-01)

The effects of hypoxia on the anti-tumour immune response
by: Macklin, P
Published: (2021)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
by: Yosuke Shibata, et al.
Published: (2023-11-01)

Arenaviruses: Old viruses present new solutions for cancer therapy
by: Paweł Stachura, et al.
Published: (2023-03-01)

The promise and challenge of anti-HIV cellular immunity.
by: Borrow, P, et al.
Published: (2006)

Remodeling the tumor-immune microenvironment by anti-CTLA4 blockade enhanced subsequent anti-PD-1 efficacy in advanced nasopharyngeal carcinoma
by: Yuxiang Ma, et al.
Published: (2024-03-01)

945 Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity and impacts anti-PD-L1 efficacy
by: Thomas Gajewski, et al.
Published: (2023-11-01)

Key differences between anti-PD-1/PD-L1 inhibitors
by: N. V. Zhukova, et al.
Published: (2022-06-01)

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
by: A. Capasso, et al.
Published: (2019-02-01)

SAPOSIN-LIKE PROTEINS IN ANTI-INFECTIOUS IMMUNE RESPONSE
by: V. V. Yeremeev, et al.
Published: (2014-07-01)

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
by: Chuah, Samuel, et al.
Published: (2022)

1076 Discovery and evaluation of an anti-IL18BP antibody to enhance anti-tumor immunity
by: Deborah A Witherden, et al.
Published: (2023-11-01)

S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
by: Huihuang Li, et al.
Published: (2023-09-01)

Resonance of fatty acid metabolism and immune infiltration in anti-PD-1 monotherapy for breast cancer
by: Andi Zhao, et al.
Published: (2024-06-01)

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
by: Jinghan Li, et al.
Published: (2024-02-01)

Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
by: Yang Zhao, et al.
Published: (2022-03-01)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
by: Janna Krueger, et al.
Published: (2021-01-01)

Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy
by: Anna Brichkina, et al.
Published: (2023-12-01)